REG - ReNeuron Group plc - Block listing application

ReNeuronAnnouncement

01/03/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230301:nRSA3900Ra&default-theme=true

RNS Number : 3900R  ReNeuron Group plc  01 March 2023

ReNeuron Group plc

("ReNeuron" or "the Group" or the "Company")

 

Block listing application

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, announces that an application has been made to the London Stock
Exchange for a block listing of securities in respect of 5,254,368 Ordinary
Shares of 1p each (the "New Ordinary Shares") to be admitted to trading on
AIM. It is expected that admission will become effective on or around 2 March
2023.

 

The New Ordinary Shares will be issued when necessary, in order to satisfy the
issue of shares pursuant to the exercise of options issued under the Company's
share schemes. When issued, the New Ordinary Shares will be credited as fully
paid and will rank pari passu in all respects with the existing Ordinary
Shares of 1p each in the capital of the Company.

 

 

 
ENDS

 

 

 

Enquiries:

 

 ReNeuron                                                  www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                                       Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Liberum Capital Limited (NOMAD and Joint Broker)          +44 (0)20 3100 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)                    +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                  +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                           (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings  +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About ReNeuron

 

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSQVLFLXLLBBBX